Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, 58# Zhongshan Road 2, Guangzhou, 510080, People's Republic of China.
Clinical Research Unit, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China.
Eur Radiol. 2021 Jul;31(7):5379-5389. doi: 10.1007/s00330-020-07551-9. Epub 2021 Jan 6.
Restricted mean survival time (RMST) has been increasingly used to assess the treatment effect. We aimed to evaluate a treatment effect of radiofrequency ablation (RFA) versus liver transplantation (LT) and surgical resection (SR) for hepatocellular carcinoma (HCC) within Milan criteria by using an adjusted RMST.
A total of 7,218 HCC patients (RFA, 3,327; LT, 2,332; SR 1,523) within Milan criteria were eligible for this retrospectively study. The RMST using inverse probability of treatment weighting (IPTW) adjustment were applied to estimate the treatment effect between RFA and LT, RFA, and SR groups.
The 3-, 5-, and 10-year IPTW-adjusted difference in RMST of OS for LT over RFA were + 4.5, + 12.4, and + 36.3 months, respectively. For SR versus RFA group, the survival benefit was + 2.3, + 6.1, and + 15.8 months at 3, 5, and 10 years, respectively. But the incremental survival benefit of SR over RFA was only half than that of LT over RFA. In the subgroup of solitary tumor ≤ 2 cm, the adjusted RMST of RFA versus SR was comparable with no statistical differences. Beyond that, in comparison with RFA, a notably greater efficacy of LT and SR was consistently across all subgroups with solitary HCC > 2.0 cm, AFP positive or negative, and fibrosis score 0-4 or 5-6.
RMST provides a measure of absolute survival benefit at a specific time point. Using IPTW-adjusted RMST, we showed that the incremental survival benefit of SR over RFA was about half than that of LT over RFA.
• The restricted mean survival time offers an intuitive, clinically meaningful interpretation to quantify the treatment effect than the hazard ratio. • Liver transplantation and surgical resection provided better overall survival compared to radiofrequency ablation for HCC patients within Milan criteria, but RFA and SR provide equivalent long-term overall survival for solitary HCC ≤ 2 cm. • The incremental survival benefit of surgical resection over radiofrequency ablation was only half than that of liver transplantation over radiofrequency ablation.
限制平均生存时间(RMST)已被越来越多地用于评估治疗效果。我们旨在通过调整 RMST 来评估符合米兰标准的肝细胞癌(HCC)患者中射频消融(RFA)与肝移植(LT)和手术切除(SR)治疗效果的差异。
本回顾性研究共纳入符合米兰标准的 7218 例 HCC 患者(RFA 组 3327 例,LT 组 2332 例,SR 组 1523 例)。采用逆概率治疗加权(IPTW)调整 RMST 来估计 RFA 与 LT、RFA 与 SR 组之间的治疗效果差异。
LT 相对于 RFA 的 3 年、5 年和 10 年 IPTW 调整后 RMST 差异分别为+4.5、+12.4 和+36.3 个月。对于 SR 相对于 RFA 组,3 年、5 年和 10 年的生存获益分别为+2.3、+6.1 和+15.8 个月。但 SR 相对于 RFA 的生存获益仅为 LT 相对于 RFA 的一半。在单发肿瘤≤2cm 的亚组中,RFA 相对于 SR 的调整 RMST 无统计学差异。除此之外,与 RFA 相比,在所有 HCC 单发肿瘤>2.0cm、AFP 阳性或阴性以及纤维化评分 0-4 或 5-6 的亚组中,LT 和 SR 的疗效均显著提高。
RMST 提供了特定时间点绝对生存获益的衡量标准。使用 IPTW 调整的 RMST,我们发现 SR 相对于 RFA 的生存获益增加幅度约为 LT 相对于 RFA 的一半。
RMST 提供了一种比风险比更直观、更有临床意义的治疗效果衡量标准。
对于符合米兰标准的 HCC 患者,LT 和 SR 提供了比 RFA 更好的总体生存率,但 RFA 和 SR 为单发肿瘤≤2cm 的 HCC 患者提供了等效的长期总体生存率。
SR 相对于 RFA 的生存获益增加幅度仅为 LT 相对于 RFA 的一半。